Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tanCART19/20 in AQP4-IgG+ NMOSD
NCT03605238Phase 1Withdrawn
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2018
- Primary completion
- Aug 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of tanCART19/20 in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Chinese PLA General Hospital. Planned start Aug 2018; status: withdrawn.
02
Drugs
tanCART19/20
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT03605238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605238.